© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2016
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Conferences

Coffee Could Protect Against Non-Alcoholic Fatty Liver Disease

Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study.

Success for 8 Weeks of Gilead’s All-Genotype Hepatitis C Regimen

Gilead’s experimental hepatitis C treatment for all genotypes boasted a high success rate among those treated for the first time.

Studies to Begin of $300 Generic Hepatitis C Treatment for International Use

Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.

People Beat Hepatitis C Just As Well When Treated by Nonspecialists

People who receive hepatitis C treatment from community-based treatment providers are cured at the same rate as those who see specialists.
Jeff Lazarus

Without a Vaccine, Eliminating Hepatitis C Will Be a Huge Challenge

Jeffrey Lazarus interviews experts from the European Liver Patients Association about the changing field of viral hepatitis

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics
Thinkstock

Whether a Liver Transplant Has Hepatitis C Has No Bearing on Outcome for People With Hep C

People with hepatitis C do just as well with a liver transplant that is infected with the virus as those receiving an uninfected organ.

AbbVie’s Viekira Pak Works Just As Well in Those With Hepatitis C Drug Resistance

Having resistance to a particular class of hepatitis C drugs does not affect the likelihood of a cure with AbbVie’s Viekira Pak.

New Algorithm Predicts Who Will Benefit From End-Stage Liver Disease Treatment

Researchers have developed a new algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease.

Excellent Real-World Results for AbbVie’s Hepatitis C Regimen Viekira Pak

AbbVie’s hepatitis C virus (HCV) regimen Viekira Pak boasted excellent safety and efficacy data in a large, ongoing, real-world trial.

New Tenofovir Is As Good As, Safer Than Old Version for Hepatitis B

Gilead’s tenofovir alafenamide (TAF) combats hepatitis B comparably to and is safer than Viread (tenofovir disoproxil fumarate, or TDF).

Hot topics

Forums: Support and discussion
Blogs: The community speaks
Jeff Lazarus

Hepatitis: The International Liver Congress Nine Years Later

Jeffrey Lazarus talks here about the changes he has seen in the hepatitis field since the International Liver Congress in 2007.

European HIV-Positive Gay Men Cured of Hepatitis C Are Reinfected at Very High Rate

Western European men who have sex with men who have HIV and are cured of hepatitis C virus are reinfected with HCV at a very high rate.

Can You Get Away With an Even Shorter Hepatitis C Treatment?

Research suggests that some people are taking hep C therapy for longer periods than they actually need.

Those Who Fail Hepatitis C Treatment Have an Excellent Subsequent Shot

People retreated for hepatitis C virus after a failed cure attempt have a very good chance of achieving a cure.
Lucinda K. Porter, RN

The Latest Hepatitis C Data from EASL

Highlights from the 2016 International Liver Congress
Advertisement
Science News
Newsfeed
Features
Ask Hep